Phase 2 study of the MEK inhibitor PD-0325901 in patients with advanced non-small cell lung cancer
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2009
At a glance
- Drugs PD 325901 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Mar 2009 Last checked against ClinicalTrials.gov. record.
- 23 Aug 2007 Status changed from in progress to discontinued.
- 29 Aug 2006 Status change